News25/Ratings0
Latest news
25 items- PRHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board ChairMs. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka
- SECSEC Form SC 13G filedSC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)
- SECSEC Form 8-K filed8-K - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)
- SECSEC Form D filedD - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)
- SECSEC Form 3: Trust Family Lindquist L. Susan claimed ownership of 1,184,561 units of Common Stock3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form SC 13G filedSC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)
- SECSEC Form SC 13D filedSC 13D - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)
- SECSEC Form SC 13G filedSC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)
- SECSEC Form 8 filed8-K - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)
- SECSEC Form 4 filed4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECPICKETT CECIL B acquired 6158 shares in 1 transactions4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 4 filed4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 4 filed4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECMohsen Paulash acquired 36428 shares in 1 transactions4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 4 filed4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 4 filed4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECKelly Jeffery W. acquired 6158 shares in 1 transactions4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECHeyman Richard A. acquired 6158 shares in 1 transactions4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECArkowitz David acquired 4347 shares in 1 transactions4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECCOLES N ANTHONY acquired 742559 shares in 2 transactions4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 3 filed3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 3 filed3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 3 filed3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 3 filed3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
- SECSEC Form 3 filed3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)
PTI FAQ
5 questionsWhere does PTI stock trade?
Proteostasis Therapeutics, Inc. (PTI) is listed on NASDAQ.What sector and industry is PTI in?
Proteostasis Therapeutics, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Proteostasis Therapeutics, Inc. go public?
Proteostasis Therapeutics, Inc. (PTI) completed its IPO in 2016.What companies are similar to PTI?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare PTI side-by-side with any of them on Quantisnow.How can I track PTI on Quantisnow?
Quantisnow aggregates Proteostasis Therapeutics, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTI to receive live email and push alerts on every new disclosure.